SYH 2053
Alternative Names: SYH-2053Latest Information Update: 19 Feb 2024
At a glance
- Originator CSPC Zhongnuo Pharmaceutical
- Class Amides; Amino sugars; Antihyperlipidaemics; Drug conjugates; Small interfering RNA
- Mechanism of Action PCSK9 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dyslipidaemias; Hypercholesterolaemia